In the early 2000s the available mTOR inhibitor limus drugs, available for coronary stenting, were developed for systemic application. Biosensors developed its own proprietary limus technology by focusing during the early stages of drug development on its use for vascular technologies.
The Research and Development team developed several versions of Biolimus, through a number of iterations ultimately decided to focus on BA9™ (Biolimus A9™), as the best option for coronary stent application. Consequently, Biosensors' proprietary limus drug BA9™ was used within its BioMatrix™ DES family and BioFreedom™ DCS.
1. Data on file Biosensors International Group Ltd – Report RD – 00020 - Validation / Verification of ElogPoct Determination Method and Measurement of ElogPoct for Zotarolimus